A compound of Formula: or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: m is 1 or 2; n is 1 or 2; wherein: W is CH 2 when (m + n) is 2 or 3; or W is CH 2, O, or NH when (m + n) is 4; R 1 is -(CR d R d) a OH, -(CR d R d) a COOH, -(CR d R d) a C NR c R c, -(CR d R d) a C NHS 2 (C 1 - 3 alkyl), -(CR d R d) a C NHS 2 (aryl), or -(CR d R d) a tetrazolyl; each R 2 is independently halo, C 1-4 alkyl, C 1-2 haloalkyl, -OH, C 1-3 alkoxy, and/or -NR c R c; R 3 and R 4 are independently H and/or C 1-6 alkyl, or R 3 and R 4 together with the carbon atom to which they are attached, form a 3- to 6-membered ring containing zero or 1 heteroatom selected from O and N; R 5 is H or C 1-4 alkyl; each R 6 is independently C 1-3 alkyl, halo, C 1-3 haloalkyl, -CN, -OH, C 1-3 alkoxy, and/or C 1-3 haloalkoxy; A is Q is a 5-membered monocyclic heteroaryl group having 1 to 3 heteroatoms independently selected from N, O, and/or S, wherein said heteroaryl group is substituted with R a and zero or 1 R b, provided that when A is Q is not 2-furan-2-yl, 4-thiazolyl, 4-oxazolyl, or 1,2,3-triazolyl; R a is C 2-6 alkyl, C 2-4 haloalkyl, C 3-6 cycloalkyl, tetrahydropyranyl, or a cyclic group selected from phenyl, benzyl, and 5- to 6-membered monocyclic heteroaryl groups having 1 to 3 heteroatoms independently selected from N, O, and/or S, wherein said cyclic group is substituted with zero, 1, 2, or 3 substituents independently selected from halo, -CN, -OH, C 1-4 alkyl, C 1-4 alkoxy, C 1-3 haloalkyl, and/or C 1-2 haloalkoxy; R b is C 1-3 alkyl or C 1-3 haloalkyl, provided that if R a is alkyl then R b is C 1-3 haloalkyl; each R c is independently H and/or C 1-4 alkyl; each R d is independently H, -OH, C 1-4 alkyl, C 1-4 haloalkyl, and/or C 1-4 alkoxy; a is zero, 1, 2, or 3; t is zero, 1, 2, 3, or 4; and x is zero, 1, or 2; with the proviso that the following compounds are excluded: and m is 1 or 2; n is 1 or 2; W is CH 2 when (m + n) is 2 or 3; or W is CH 2, O, or NH when (m + n) is 4; R 1 is -(CR d R d) a OH, -(CR d R d) a COOH, -(CR d R d) a C NR c R c, -(CR d R d) a C NHS 2 (C 1 - 3 alkyl), -(CR d R d) a C NHS 2 (aryl), or -(CR d R d) a tetrazolyl; each R 2 is independently halo, C 1-4 alkyl, C 1-2 haloalkyl, -OH, C 1-3 alkoxy, and/or -NR c R c; R 3 and R 4 are independently H and/or C 1-6 alkyl, or R 3 and R 4 together with the carbon atom to which they are attached, form a 3- to 6-membered ring containing zero or 1 heteroatom selected from O and N; R 5 is H or C 1-4 alkyl; each R 6 is independently C 1-3 alkyl, halo, C 1-3 haloalkyl, -CN, -OH, C 1-3 alkoxy, and/or C 1-3 haloalkoxy; A is Q is a 5-membered monocyclic heteroaryl group having 1 to 3 heteroatoms independently selected from N, O, and/or S, wherein said heteroaryl group is substituted with R a and zero or 1 R b, provided that when A is Q is not 2-furan-2-yl, 4-thiazolyl, 4-oxazolyl, or 1,2,3-triazolyl; R a is C 2-6 alkyl, C 2-4 haloalkyl, C 3-6 cycloalkyl, tetrahydropyranyl, or a cyclic group selected from phenyl, benzyl, and 5- to 6-membered monocyclic heteroaryl groups having 1 to 3 heteroatoms independently selected from N, O, and/or S, wherein said cyclic group is substituted with zero, 1, 2, or 3 substituents independently selected from halo, -CN, -OH, C 1-4 alkyl, C 1-4 alkoxy, C 1-3 haloalkyl, and/or C 1-2 haloalkoxy; R b is C 1-3 alkyl or C 1-3 haloalkyl, provided that if R a is alkyl then R b is C 1-3 haloalkyl; each R c is independently H and/or C 1-4 alkyl; each R d is independently H, -OH, C 1-4 alkyl, C 1-4 haloalkyl, and/or C 1-4 alkoxy; a is zero, 1, 2, or 3; t is zero, 1, 2, 3, or 4; and x is zero, 1, or 2;